MedTech & Diagnostics
Bioventus Executive Compensation (FY25)
BVS · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025 ◇ Robert Claypoole |
Velarion Member: every covered company in MedTech & Diagnostics, with dashboards, peer screens and board-ready briefs. Three seats, one year.
The paid brief on Bioventus
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Data as of October 17, 2026Latest filing (DEF 14A): April 22, 2026
4 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Member, one year
205 figures on this page, cited to the filing that reported them. See the citations
This company is not required to report a chief executive pay ratio.
More on Bioventus
Five data products on this company. Each one is requested through the developer setup page.
- Peer Disclosure Audit$5The comparison companies this board named, each one tied to the filing that lists it.How to get Peer Disclosure Audit
- Governance Provisions PullfreeThe governance provisions as the proxy states them: board leadership, committee membership, and shareholder rights.How to get Governance Provisions Pull
- Say-on-Pay Risk Signal$9A risk band for the next say-on-pay vote, with the support history and the peer comparison behind it.How to get Say-on-Pay Risk Signal
- NEO Comp Report$24Every named executive officer’s pay by element and year, with the citation behind each figure.How to get NEO Comp Report
- Board Comp Report$24What each non-employee director was paid, the standing fee schedule, and the equity each one holds at year end.How to get Board Comp Report
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Robert Claypoole: $6,379,010 → $4,299,108 (32.6% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Bioventus' chief executive and what were they paid?
Robert Claypoole, President and Chief Executive Officer, received $4,299,108 in total compensation for fiscal 2025. Claypoole's total was 32.6% lower than the $6,379,010 reported for fiscal 2024.
What was Bioventus' say-on-pay result?
As an emerging growth company, the company is exempt from the advisory say-on-pay vote.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Kenneth Reali Former Chief Executive Officer | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
Mark Singleton Senior Vice President & Chief Financial Officer | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
John Nosenzo Former Senior Vice President & Chief Commercial Officer Departed during or after this year | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Alessandra Pavesio Former Senior Vice President & Chief Science Officer Departed during or after this year | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Anthony Bihl Former Interim Chief Executive Officer Departed during or after this year | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Kenneth Reali Former Chief Executive Officer Departed during or after this year | ◇ | ◇ | — | — | — | — | ◇ | ◇ |
Mark Singleton Senior Vice President & Chief Financial Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Anthony D'Adamio Senior Vice President & General Counsel | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Robert Claypoole President & Chief Executive Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Mark Singleton Senior Vice President & Chief Financial Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Anthony D'Adamio Senior Vice President & General Counsel | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Robert Claypoole President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Mark Singleton Senior Vice President and Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Anthony D'Adamio Senior Vice President and General Counsel | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Anthony D'Adamio | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Anthony D'Adamio | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Anthony D'Adamio | MSU | ◇ | ◇ | ◇ | — | — | — | — |
| Mark Singleton | MSU | ◇ | ◇ | ◇ | — | — | — | — |
| Mark Singleton | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Mark Singleton | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Robert E. Claypoole, Jr. | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Robert E. Claypoole, Jr. | MSU | ◇ | ◇ | ◇ | — | — | — | — |
| Robert E. Claypoole, Jr. | RSU | ◇ | — | — | ◇ | — | — | ◇ |
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Anthony D'Adamio | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Robert Claypoole | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Mark Singleton | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
Anthony D'Adamio
Senior Vice President and General Counsel · Employment agreement
| Severance multiple | ◇ |
Mark Singleton
Senior Vice President and Chief Financial Officer · Employment agreement
| Severance multiple | ◇ |
Robert Claypoole
President and Chief Executive Officer · Employment agreement
| Severance multiple | ◇ |
| Change-in-control multiple | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
William A. Hawkins Board chair | ◇ | ◇ | — | — | — | — | ◇ |
Susan M. Stalnecker | ◇ | ◇ | — | — | — | — | ◇ |
John A. Bartholdson | ◇ | ◇ | — | — | — | — | ◇ |
Mary Kay Ladone | ◇ | ◇ | — | — | — | — | ◇ |
Patrick J. Beyer | ◇ | ◇ | — | — | — | — | ◇ |
Michelle McMurry-Heath | ◇ | ◇ | — | — | — | — | ◇ |
Guido J. Neels | ◇ | ◇ | — | — | — | — | ◇ |
Guy P. Nohra | ◇ | ◇ | — | — | — | — | ◇ |
Philip G. Cowdy | ◇ | ◇ | — | — | — | — | ◇ |
Martin P. Sutter | — | ◇ | — | — | — | — | ◇ |
Robert E. Claypoole and Ajay Dhankhar served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as restricted stock units.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Say-on-pay history
Shareholder support for the compensation program, by year.
This company is an emerging growth company and is exempt from the advisory vote on executive compensation. There is no vote to report.
Velarion Pro: every company page, peer tools and exports, one seat
One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Robert Claypoole (President and Chief Executive Officer), FY2025 total compensation $4,299,108 (base salary $824,110) [exec_comp, SEC accession 0001665988-26-000014, filed 2026-04-22]What this page does not include
Everything above is a fact Bioventus disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
205 figures on this page, cited to the filing that reported them.
205 cited to the filing
Documents cited
- 0001665988-26-000014Director Compensation · EQUITY COMPENSATION PLAN INFORMATION · Outstanding Equity Awards at 202 · Proxy severance section · and 1 more section
- 0001628280-25-018715Summary Compensation Table
- 0001628280-24-0184312023 Summary Compensation Table
- 0001193125-23-1202322022 Summary Compensation Table
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Bioventus executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/BVS (accessed 2026).
Short form: data: Velarion
The paid brief for Bioventus
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
4 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Bioventus and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
MedTech & Diagnostics rankings
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}